Advertisement

Pathology & Oncology Research

, Volume 18, Issue 2, pp 293–298 | Cite as

High-mobility Group Box 1 is Associated with Clinicopathologic Features in Patients with Hepatocellular Carcinoma

  • Wei Jiang
  • Zhiming WangEmail author
  • Xinying Li
  • Xuegong Fan
  • Yankun Duan
Research

Abstract

High-mobility group box 1(HMGB1) has been associated with many human cancers, but the role of HMGB1 in hepatocellular carcinoma (HCC) remains unclear. The aim of this study is to investigate the expression of HMGB1 in human HCC with regard to its clinical significance. Twelve cases of normal liver tissues, 34 cases of HCC and the corresponding liver tissue just around the tumor (LAT) were collected. Then, all the samples were subjected to clinicopathologic examination, reverse transcription–polymerase chain reaction (RT–PCR), Western-blot (WB) and immunohistochemical analysis for the expression of HMGB1. The relationships between HMGB1 mRNA expression and clinicopathologic parameters were analyzed. RT–PCR demonstrated that the expression of relative HMGB1 mRNA (HMGB1/GAPDH) was 0.854 ± 0.172; the highest in the tissue of HCC, significantly up-regulated compared with that of 0.527 ± 0.155 in LAT and of 0.405 ± 0.087 in normal liver tissues (P < 0.001). HMGB1 mRNA overexpression was significantly associated with Edmondson stage, TNM stage, vascular invasion and capsule invasion. Western-blot showed the expression of HMGB1 protein in HCC also as the highest among all the groups. Furthermore this overexpression revealed by immunostaining was predominantly localized in the nuclei of HCC; whereas, none of the stains were seen in normal liver cells and only a trace of it was detected in the cytoplasm of LAT cells. Our results suggested the overexpression of HMGB1 might be an important pathogenetic factor in HCC. The mechanisms of HMGB1 in HCC genesis, development and its possible diagnostic and prognostic roles need to be further explored.

Keywords

Hepatocellular carcinoma (HCC) Clinicopathology High-mobility group box 1(HMGB1) Reverse transcription–polymerase chain reaction (RT–PCR) Gene expression 

Abbreviations

HMGB1

High-mobility group box 1

HCC

Hepatocellular carcinoma

LAT

Liver tissue just around the tumor

RT–PCR

Reverse transcription–polymerase chain reaction

WB

Western-blot

Notes

Acknowledgements

The authors thank the patients who participated in this study, and all the staffs who assisted with the sample collection and pre-treatment in operation room.

References

  1. 1.
    Srivatanakul P, Sriplung H, Deerasamee S (2004) Epidemiology of liver cancer: an overview. Asian Pac J Cancer Prev 5:118–125PubMedGoogle Scholar
  2. 2.
    Yao DF, Dong ZZ, Yao M (2007) Specific molecular markers in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 6:241–247PubMedGoogle Scholar
  3. 3.
    El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557–2576PubMedCrossRefGoogle Scholar
  4. 4.
    Bosch FX, Ribes J, Cleries R et al (2005) Epidemiology of hepatocellular carcinoma. Clin Liver Dis 9:191–211PubMedCrossRefGoogle Scholar
  5. 5.
    Javaherian K, Liu JF, Wang JC (1978) Nonhistone proteins HMG1 and HMG2 change the DNA helical structure. Science 199:1345–1346PubMedCrossRefGoogle Scholar
  6. 6.
    Lotze MT, Tracey KJ (2005) High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5:331–342PubMedCrossRefGoogle Scholar
  7. 7.
    Czura CJ, Wang H, Tracey KJ (2001) Dual roles for HMGB1: DNA binding and cytokine. J Endotoxin Res 7:315–321PubMedCrossRefGoogle Scholar
  8. 8.
    Muller S, Scaffidi P, Degryse B et al (2001) New EMBO members’ review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. EMBO J 20:4337–4340PubMedCrossRefGoogle Scholar
  9. 9.
    Kostova N, Zlateva S, Ugrinova I et al (2010) The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Mol Cell Biochem 337:251–258PubMedCrossRefGoogle Scholar
  10. 10.
    Akaike H, Kono K, Sugai H et al (2007) Expression of high mobility group box chromosomal protein-1 (HMGB-1) in gastric cancer. Anticancer Res 27:449–457PubMedGoogle Scholar
  11. 11.
    Brezniceanu ML, Völp K, Bösser S et al (2003) HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J 17:1295–1297PubMedGoogle Scholar
  12. 12.
    Wu D, Ding Y, Wang S et al (2008) Increased expression of high mobility group box 1 (HMGB1) is associated with progression and poor prognosis in human nasopharyngeal carcinoma. J Pathol 216:167–175PubMedCrossRefGoogle Scholar
  13. 13.
    Liu Y, Xie C, Zhang X et al (2010) Elevated expression of HMGB1 in squamous-cell carcinoma of the head and neck and its clinical significance. Eur J Cancer 46:3007–3015PubMedCrossRefGoogle Scholar
  14. 14.
    Schlueter C, Weber H, Meyer B et al (2005) Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am J Pathol 166:1259–1263PubMedCrossRefGoogle Scholar
  15. 15.
    Dong Xda E, Ito N, Lotze MT et al (2007) High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother 30:596–606PubMedCrossRefGoogle Scholar
  16. 16.
    Kuniyasu H, Oue N, Wakikawa A et al (2002) Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 196:163–170PubMedCrossRefGoogle Scholar
  17. 17.
    Edmondson HA, Steiner PE (1954) Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 7:462–503PubMedCrossRefGoogle Scholar
  18. 18.
    Greene FL, Page DL, Fleming ID et al (2002) AJCC cancer staging manual, 6th edn. Springer, New YorkGoogle Scholar
  19. 19.
    Thomas JO, Travers AA (2001) HMG1 and 2, and related ‘architectural’ DNA-binding proteins. Trends Biochem Sci 26:167–174PubMedCrossRefGoogle Scholar
  20. 20.
    Ghavami S, Rashedi I, Dattilo BM et al (2008) S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. J Leukoc Biol 83:1484–1492PubMedCrossRefGoogle Scholar
  21. 21.
    Palumbo R, Galvez BG, Pusterla T et al (2007) Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-kappaB activation. J Cell Biol 179:33–40PubMedCrossRefGoogle Scholar
  22. 22.
    Gardella S, Andrei C, Ferrera D et al (2002) The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep 3:995–1001PubMedCrossRefGoogle Scholar
  23. 23.
    Bonaldi T, Talamo F, Scaffidi P et al (2003) Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 22:5551–5560PubMedCrossRefGoogle Scholar
  24. 24.
    Cheng BQ, Jia CQ, Liu CT et al (2008) Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Dig Liver Dis 40:446–452PubMedCrossRefGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2011

Authors and Affiliations

  • Wei Jiang
    • 1
  • Zhiming Wang
    • 1
    Email author
  • Xinying Li
    • 1
  • Xuegong Fan
    • 2
  • Yankun Duan
    • 2
  1. 1.Department of General Surgery, Xiangya HospitalCentral South UniversityChangshaChina
  2. 2.Department of Infectious Diseases, Xiangya HospitalCentral South UniversityChangshaChina

Personalised recommendations